We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FROG:NASDAQJFrog Ltd. Analysis

Data as of 2026-05-19 - not real-time

$67.91

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

JFrog (FROG) is trading at $67.91, roughly 17% above its DCF‑derived fair value of $56.92, indicating a premium valuation. The forward P/E of 60.5 far exceeds the industry average of 38.2, reinforcing the overvalued label. Nonetheless, the company posted a 25% year‑over‑year revenue increase to $531.8 M, with cloud revenues now representing just over 50% of the mix. Management forecast FY 2026 revenue of $628‑$632 M and announced a $300 M share buyback, fueling recent investor enthusiasm. Gross margins remain robust at 77%, but operating and net margins are still negative, and trailing EPS is –$0.53, highlighting the profitability gap. The “strong buy” analyst consensus (20 analysts) reflects optimism about the growth trajectory despite current losses.
On the technical side, the 20‑day SMA ($55.23) sits well below the current price, and both the MACD line (5.80) and its bullish signal reinforce upward momentum. However, the RSI of 71.8 places the stock in overbought territory, suggesting a near‑term correction risk. Volume is increasing, and the beta of ~1.27 signals higher sensitivity to market swings, consistent with the 30‑day volatility of 81%. The combination of strong top‑line growth, elevated valuation, and heightened volatility leads to a medium‑to‑high risk profile. Given the upside potential from continued cloud adoption and cash‑rich balance sheet, a cautious buy is warranted for the short and medium horizons. Over the longer term, investors should monitor margin improvement and cash‑flow conversion before confirming a sustained upside thesis.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover
  • Strong revenue growth and cloud mix
  • Overbought RSI indicating near‑term pullback risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Projected FY2026 revenue $628‑$632 M
  • $300 M share buyback supporting price
  • Improving cash flow despite operating losses

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • High gross margin and cash reserves
  • Long‑term demand for software supply‑chain solutions
  • Potential margin expansion to achieve profitability

Key Metrics & Analysis

Financial Health

Revenue Growth25.20%
Profit Margin-13.50%
P/E Ratio60.5
ROE-8.65%
ROA-4.32%
Debt/Equity1.40
P/B Ratio9.2
Op. Cash Flow$145.7M
Free Cash Flow$174.9M
Industry P/E38.2

Technical Analysis

TrendNeutral
RSI71.8
Support$42.93
Resistance$72.06
MA 20$55.23
MA 50$48.78
MA 200$51.54
MACDBullish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Fair Value$56.92
Target Price$79.45
Upside/Downside16.99%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.27
Volatility81.27%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.